These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 33614352)

  • 21. The Effect of H
    Shim YK; Kim N
    Korean J Gastroenterol; 2017 Jul; 70(1):4-12. PubMed ID: 28728310
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vonoprazan Fumarate for the Treatment of Gastric Ulcers: A Short Review on Emerging Data.
    Marabotto E; Ziola S; Savarino V; Giannini EG; Furnari M; Bodini G; Zingone F; Ghisa M; Barberio B; Zentilin P; Savarino E
    Clin Exp Gastroenterol; 2020; 13():99-104. PubMed ID: 32346304
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Role of Proton Pump Inhibitors in the Management of Upper Gastrointestinal Disorders.
    Ali Khan M; Howden CW
    Gastroenterol Hepatol (N Y); 2018 Mar; 14(3):169-175. PubMed ID: 29928161
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Suppression of acid secretion in peptic ulcer disease.
    Feldman M
    J Clin Gastroenterol; 1995; 20 Suppl 1():S1-6. PubMed ID: 7673607
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lansoprazole and omeprazole in the treatment of acid peptic disorders.
    Blum RA
    Am J Health Syst Pharm; 1996 Jun; 53(12):1401-15. PubMed ID: 8781686
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proton Pump Inhibitors: Review of Emerging Concerns.
    Nehra AK; Alexander JA; Loftus CG; Nehra V
    Mayo Clin Proc; 2018 Feb; 93(2):240-246. PubMed ID: 29406201
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proton pump inhibitor-induced gut dysbiosis and immunomodulation: current knowledge and potential restoration by probiotics.
    Kiecka A; Szczepanik M
    Pharmacol Rep; 2023 Aug; 75(4):791-804. PubMed ID: 37142877
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases.
    Welage LS; Berardi RR
    J Am Pharm Assoc (Wash); 2000; 40(1):52-62; quiz 121-3. PubMed ID: 10665250
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potassium-competitive acid blockers: Advanced therapeutic option for acid-related diseases.
    Inatomi N; Matsukawa J; Sakurai Y; Otake K
    Pharmacol Ther; 2016 Dec; 168():12-22. PubMed ID: 27514776
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders.
    Cheer SM; Prakash A; Faulds D; Lamb HM
    Drugs; 2003; 63(1):101-33. PubMed ID: 12487624
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety of the long-term use of proton pump inhibitors.
    Thomson AB; Sauve MD; Kassam N; Kamitakahara H
    World J Gastroenterol; 2010 May; 16(19):2323-30. PubMed ID: 20480516
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proton pump inhibitors: use and misuse in the clinical setting.
    Savarino V; Marabotto E; Zentilin P; Furnari M; Bodini G; De Maria C; Pellegatta G; Coppo C; Savarino E
    Expert Rev Clin Pharmacol; 2018 Nov; 11(11):1123-1134. PubMed ID: 30295105
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Results of an intervention in an academic Internal Medicine Clinic to continue, step-down, or discontinue proton pump inhibitor therapy related to a tennessee medicaid formulary change.
    Ramser KL; Sprabery LR; Hamann GL; George CM; Will A
    J Manag Care Pharm; 2009 May; 15(4):344-50. PubMed ID: 19422274
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel effects other than antisecretory action and off-label use of proton pump inhibitors.
    Suzuki H; Hibi T
    Expert Opin Pharmacother; 2005 Jan; 6(1):59-67. PubMed ID: 15709883
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas.
    Jensen RT
    Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):4-19. PubMed ID: 16433886
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Recommendation for the prevention and treatment of non-steroidal anti-inflammatory drug-induced gastrointestinal ulcers and its complications].
    ;
    Zhonghua Nei Ke Za Zhi; 2017 Jan; 56(1):81-85. PubMed ID: 28056333
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Duodenal ulcer and gastroesophageal reflux disease today: long-term therapy--a sideways glance.
    Bardhan KD
    Yale J Biol Med; 1996; 69(3):211-24. PubMed ID: 9165690
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of proton pump inhibitors in adults in France: a nationwide drug utilization study.
    Lassalle M; Le Tri T; Bardou M; Biour M; Kirchgesner J; Rouby F; Dumarcet N; Zureik M; Dray-Spira R
    Eur J Clin Pharmacol; 2020 Mar; 76(3):449-457. PubMed ID: 31838548
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rabeprazole: a second-generation proton pump inhibitor in the treatment of acid-related disease.
    Pallotta S; Pace F; Marelli S
    Expert Rev Gastroenterol Hepatol; 2008 Aug; 2(4):509-22. PubMed ID: 19072398
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proton pump inhibitors for preventing non-steroidal anti-inflammatory drug induced gastrointestinal toxicity: a systematic review.
    Yang M; He M; Zhao M; Zou B; Liu J; Luo LM; Li QL; He JH; Lei PG
    Curr Med Res Opin; 2017 Jun; 33(6):973-980. PubMed ID: 28076696
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.